Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species — mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP’s plans for the continued development of ATL1103.

More: continued here